Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria

Diabetes Res Clin Pract. 2014 Mar;103(3):373-81. doi: 10.1016/j.diabres.2013.12.052. Epub 2014 Jan 8.

Abstract

Predisposition to genital infections and urinary tract infections (UTIs) in type 2 diabetes mellitus (T2DM) results from several factors such as glucosuria, adherence of bacteria to the uroepithelium and immune dysfunction. The tendency to develop these infections could be even higher in patients with T2DM treated with the emerging class of sodium-glucose cotransporter-2 (SGLT2) inhibitors. Studies have shown that pharmacologically-induced glucosuria with SGLT2 inhibitors raises the risk of developing genital infections and, to a relatively lesser extent, UTIs. However, a definitive dose relationship of the incidence of these infections with the SGLT2 doses is not evident in the existing data. Therefore, the precise role of glucosuria as a causative factor for these infections is yet to be fully elucidated.

Keywords: Genital; Glucosuria; Infections; SGLT2; Type 2 diabetes; Urinary.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Diabetes Complications / etiology*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / urine
  • Female
  • Genital Diseases, Female / etiology*
  • Genital Diseases, Male / etiology*
  • Glycosuria / chemically induced*
  • Humans
  • Hypoglycemic Agents / adverse effects*
  • Male
  • Sodium-Glucose Transporter 2 Inhibitors
  • Urinary Tract Infections / etiology*

Substances

  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2 Inhibitors